Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.41 |
| ▸ | EBP | Q15125 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22175918 | 0.73 | SIGMAR1 (0.50) | LMNASIGMAR1EBP | |
| SCHEMBL11658380 | 0.72 | SIGMAR1 (0.34) | LMNASIGMAR1EBPTMEM97 | |
| SCHEMBL19259384 | 0.72 | SIGMAR1 (0.52) | LMNASIGMAR1EBPOPRM1OPRD1 | |
| SCHEMBL7782450 | 0.71 | SIGMAR1 (0.51) | LMNASIGMAR1EBP | |
| SCHEMBL7788022 | 0.70 | SIGMAR1 (0.54) | LMNASIGMAR1EBPOPRM1OPRD1 | |
| SCHEMBL7782520 | 0.70 | SIGMAR1 (0.54) | LMNASIGMAR1EBPOPRM1OPRD1 | |
| SCHEMBL9419931 | 0.70 | SLC6A4 (0.39) | SIGMAR1 | |
| SCHEMBL7788011 | 0.70 | SIGMAR1 (0.54) | LMNASIGMAR1EBPOPRM1OPRD1 | |
| SCHEMBL27527195 | 0.70 | SIGMAR1 (0.49) | LMNASIGMAR1EBPOPRM1OPRD1 | |
| SCHEMBL3267624 | 0.69 | KDM4E (0.47) | LMNAOPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890147-B2 | 2,3-benzodiazepines | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2018-02-13 | — | — | US | disclosed |
| EP-2885286-B1 | 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-20160129011-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2016-05-12 | — | — | US | disclosed |
| EP-2958909-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-30 | — | — | EP | disclosed |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-23 | — | — | US | disclosed |
| WO-2014128067-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129011-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | BRD4, BRDT, BICRA | LMNA 1470/4885SIGMAR1 2458/4885EBP 81/4885 |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BRD4, BET1, BRDT | LMNA 676/4885SIGMAR1 1451/4885EBP 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.